Peter Gocke

Peter Gocke

Auto-generated profile, based on publicly available information

Peter Gocke

Digital Transformation Staff Unit, Charité, Berlin, Germany

Research Focus & Metrics

Academic Career Length

34Years (1993-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2002 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Closed access
BHBurkhard Lorenz Herrmann
Burkhard Lorenz Herrmann
BSBernhard Saller
Bernhard Saller
OJOnno Eilard Janssen
Onno Eilard Janssen
PGPeter Gocke
Peter Gocke
ABAndreas Bockisch
Andreas Bockisch
MBMartina Broecker
Martina Broecker
Recent reports of the impact of estrogen receptor alpha and aromatase deficiency have shed new light on the importance of estrogen for bone formation in man. We describe a novel mutation of the CYP19 gene in a 27-yr-old homozygous male of consanguinous parents. A C to A substitution in intron V, at position -3 of the splicing acceptor site before exon VI of the CYP19 gene, is the likely cause of loss of aromatase activity. The mRNA of the patient leads to a frameshift and a premature stop codon 8 nucleotides downstream the end of exon V. Both parents were shown to be heterozygous for the same mutation. Apart from genua valga, kyphoscoliosis, and pectus carniatus, the physical examination was normal including secondary male characteristics with normal testicular size. To substitute for the deficiency, the patient was treated with 50 micro g transdermal estradiol twice weekly for 3 months, followed by 25 micro g twice weekly. After 6 months estrogen levels (1.150). Osteocalcin as a bone formation parameter increased from 13 to 52 micro g/l (normal range, 24-70) and aminoterminal collagen type I telopeptide as a bone resorption parameter increased from 62.9 to 92.4 nmol/mmol creatinine (normal range, 5-54). Semen analysis revealed oligoazoospermia (17.4 million/ml; normal >20) at baseline. After 3 months of treatment, the sperm count increased (23.1 million/ml) and decreased rapidly (1.1 million/ml) during the following 3 months. The sperm motility was reduced at baseline and decreased further during treatment. Area under the curve of insulin, C-peptide, and blood glucose levels during oral glucose tolerance test decreased after 6 months (insulin: 277 vs. 139 micro U/ml.h; C-peptide 52 vs. 15 ng/m.h; area under the curve glucose: 17316 vs. 12780 mg/d.min). Triglycerides (268 vs. 261 mmol/liter) and total cholesterol levels (176 vs. 198 mmol/liter) did not change significantly, but the low-density lipoprotein/high-density lipoprotein ratio decreased from 5.37 to 3.56 and lipoprotein (a) increased from 19.9 to 60.0 mg/dl (normal range, <30). In this rare incidence of estrogen deficiency, estrogen replacement demonstrated its importance for bone mineralization and maturation and glucose metabolism in a male carrying a novel mutation in the CYP19 gene.

31 May 2019 in Deutsches Ärzteblatt international
Verified
Journal Article
Closed access
DKDmytro Khadzhynov
Dmytro Khadzhynov
DSDanilo Schmidt
Danilo Schmidt
JHJuliane Hardt
Juliane Hardt
GRGeraldine Rauch
Geraldine Rauch
PGPeter Gocke
Peter Gocke
KSKai M. Schmidt-Ott
Kai M. Schmidt-Ott
Studies from multiple countries have shown that acute kidney injury (AKI) in hospitalized patients is associated with mortality and morbidity. There are no reliable data at present on the incidence and mortality of AKI episodes among hospitalized patients in Germany. The utility of administrative codings of AKI for the identification of AKI episodes is also unclear. In an exploratory approach, we retrospectively analyzed all episodes of AKI over a period of 3.5 years (2014-2017) on the basis of routinely obtained serum creatinine measurements in 103 161 patients whose creatinine had been measured at least twice and who had been in the hospital for at least two days. We used the "Kidney Disease: Improving Global Outcomes" (KDIGO) criteria for AKI. In parallel, we assessed the administrative coding of discharge diagnoses of the same patients with codes from the International Classification of Diseases (ICD-10-GM). Among 185 760 hospitalizations, stage 1 AKI occurred in 25 417 cases (13.7%), stage 2 in 8503 cases (4.6%), and stage 3 in 5881 cases (3.1%). AKI cases were associated with length of hospital stay, renal morbidity, and overall mortality, and this association was stage-dependent. The in-hospital mortality was 5.1% for patients with stage 1 AKI, 13.7% for patients with stage 2 AKI, and 24.8% for patients with stage 3 AKI. An administrative coding for acute kidney injury (N17) was present in only 28.8% (11 481) of the AKI cases that were identified by creatinine criteria. Like the AKI cases overall, those that were identified by creatinine criteria but were not coded as AKI had significantly higher mortality, and this association was stage-dependent. AKI episodes are common among hospitalized patients and are associated with considerable morbidity and mortality, yet they are inadequately documented and probably often escape the attention of the treating physicians.

20 December 2018 in JMIR Cancer
Verified
Journal Article
Open access
MKMaria Margarete Karsten
Maria Margarete Karsten
DSDorothee Speiser
Dorothee Speiser
CHClaudia Hartmann
Claudia Hartmann
NZNele Zeuschner
Nele Zeuschner
KLKai Lippold
Kai Lippold
JBJens-Uwe Blohmer
Jens-Uwe Blohmer
Journal of Medical Internet Research - International Scientific Journal for Medical Research, Information and Communication on the Internet #Preprint #PeerReviewMe: Warning: This is a unreviewed preprint. Readers are warned that the document has not been peer-reviewed by expert/patient reviewers or an academic editor, may contain misleading claims, and is likely to undergo changes before final publication, if accepted, or may have been rejected/withdrawn. Readers with interest and expertise are encouraged to sign up as peer-reviewer, if the paper is within an open peer-review period. Please cite this preprint only for review purposes or for grant applications and CVs (if you are the author). Background: Collecting patient reported outcome (PRO) data in a systematic way enables an objective evaluation of treatment and its related outcomes. By using the disease specific questionnaires developed by the International Consortium of Health Outcome Measurement (ICHOM) this allows for comparison between physicians, hospitals and even different countries. Objective: The aim of this pilot project was to establish a digital system to measure patient reported outcomes for new breast cancer patients who attended the Charité Breast cancer clinic. This approach should serve as a blueprint to further expand the PRO measurement to other disease entities and departments. Methods: In November 2016 we implemented a web-based system to collect PRO data at the breast center at Charité University hospital using the ICHOM data set. All new patients at the breast center were enrolled and were answering a predefined set of questions using a tablet computer. Once they start their treatment at Charité automated emails were sent to the patient at predefined treatment points. Those emails contained a web-based link through which they could access and answer questionnaires. Results: By now 541 patients have been enrolled and 2470 questionnaires initiated. 9.44% of the patients were under the age of 40, 49.7% between 40 and 60, 39.6% between 60-80 and 1.3% over the age of 80. The average return rate of questionnaires was 67%. When asked about preference regarding paper versus online questionnaires 6% of the patients between 50 to 60 , 6% between 60-70 and 13 % over 70 would prefer paper versions. Conclusions: Measuring PRO in breast cancer patients in an automated electronic version is possible across all age ranges while simultaneously achieving a high return rate.

1 February 1997 in The Thoracic and Cardiovascular Surgeon
Verified
Journal Article
Closed access
UWU. Wolfhard
U. Wolfhard
FSF. H. Splittgerber
F. H. Splittgerber
PGP. Gocke
P. Gocke
JRJ. Chr. Reidemeister
J. Chr. Reidemeister
Attempted venous cannulation with a dual-stage cannula for cardiopulmonary bypass in routine coronary revascularization led to the discoveryof an abnormal inferior vena cava in a 65-year-old patient. The operative and postoperative course of the patient were not affected by the inferior caval anomaly. The detailed infradiaphragmatic venous anatomy was elucidated later by MRI and showed bilateral inferior caval veins with azygos continuation. Although this malformation of the inferior cava is rare in adults, the occurrence should be known. Quick recognition and handling should be achieved if detected during cannulation for cardiopulmonary bypass.

1 May 2002 in Der Radiologe
Verified
Journal Article
Closed access
PDF file
PGPeter Gocke
Peter Gocke
JDJ. F. Debatin
J. F. Debatin

1 September 1999 in Acta Radiologica
Verified
Journal Article
Closed access
PDF file
PGP. Gocke
P. Gocke
CGC. Gocke
C. Gocke
KNK. Neumann
K. Neumann
PHP. Henseke
P. Henseke
RLR. Langer
R. Langer
RMR.-D. Müller
R.-D. Müller
Objective: To develop an injection protocol for intravenous administration of contrast media in abdominal and pelvic helical CT which provides optimal contrast enhancement of arterial and venous vessels. Material and Methods: for the study on a Somatom Plus 4 unit, a standard helical CT examination procedure of abdomen and pelvis consisted firstly of a native helical examination of the liver, a second one of the liver after intravenous injection of 120 ml nonionic contrast medium with a constant start delay of 50 s, and subsequently a third helical CT of the lower abdomen and pelvis. 125 patients were randomized for examination under different protocols, varying the injection flow from 2.0–4.0 ml/s and the time delay between the second and the third helical examinations from an additional 20–40 s. the efficacy of the contrast injection was checked by region of interest (ROI) measurements of HUs in aorta, inferior vena cava, and in femoral arteries and veins. the results were compared by t-test statistics. Results: A slow flow rate of 2.0 ml/s led to a higher contrast enhancement in the aorta than a flow rate of 3.0 and 4.0 ml/s. the difference between 2.0 ml/s and 4.0 ml/s was statistically significant. In the inferior vena cava, a flow of 3.0 ml/s caused a better contrast than a flow of 2.0 ml/s or 4.0 ml/s but the measurements did not reach statistical significance. the measurements in the femoral arteries and veins did not show any significant differences. Maximal enhancement in the pelvic vessels was achieved when the third helical examination was started immediately after the second one had ended. Adding any delay (20 s, 40 s) led to a reduced contrast in the pelvic vessels, with a significant reduction in aorta and femoral arteries. Conclusion: for routine abdominal and pelvic helical CT, we recommend an injection of 120 ml contrast medium with a flow rate of 3.0 ml/s. Contrast-enhanced examination of the liver should be started after 50 s, and examination of the lower abdomen and pelvis region should be performed without any further delay. This gives an appropriate contrast in the major vessels.